Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily Therapy.

The Journal of infectious diseases - 15 Jul 2016

Edlefsen Paul T, Birkmann Alexander, Huang Meei-Li, Magaret Craig A, Kee Jia Jin, Diem Kurt, Goldner Thomas, Timmler Burkhard, Stoelben Susanne, Ruebsamen-Schaeff Helga, Zimmermann Holger, Warren Terri, Wald Anna, Corey Lawrence

Abstract excerpt

BACKGROUND: Pritelivir is a novel helicase-primase inhibitor in clinical development for treatment of herpes simplex virus type 2 (HSV-2) infections. In preclinical work, resistance-mediating mutations were identified in the HSV-2 genome at 3 loci in the UL5 gene and 1 locus in UL52. METHODS: To evaluate whether daily pritelivir treatment results in emergence of resistance-mediating mutations, we analyzed HSV-2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Herpes Genitalis

Share to Herpesvirus 2, Human

Share to Pyridines

Share to Sulfonamides

Share to Thiazoles

Share to Viral Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 27056950
DOI: 10.1093/infdis/jiw129
PMCID: PMC4918824

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily Therapy.PMID 27056950Read ↗

Helicase–Primase Inhibitor Pritelivir for HSV-2 InfectionSemantic proximity Read ↗

Clinical and genotypic characteristics of antiviral-resistant herpes simplex virus 1 and 2 infections: a case series.Semantic proximity Read ↗

Six years of clinical herpes simplex virus genotypic acyclovir resistance testing confirms common resistance mechanisms and identifies novel mutationsSemantic proximity Read ↗

High prevalence but low clinical impact of acyclovir-resistant herpes simplex virus type 1 infections in patients with hematologic disorders.Semantic proximity Read ↗

Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.Semantic proximity Read ↗

Detection of HSV-1 variants highly resistant to the helicase–primase inhibitor BAY 57-1293 at high frequency in 2 of 10 recent clinical isolates of HSV-1Semantic proximity Read ↗

Surveillance of herpes simplex virus resistance to antivirals: a 4-year survey.Semantic proximity Read ↗

Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.Semantic proximity Read ↗

Resistance testing of clinical herpes simplex virus type 2 isolates collected over 4 decades.Semantic proximity Read ↗

Mismatch primer-based PCR reveals that helicase-primase inhibitor resistance mutations pre-exist in herpes simplex virus type 1 clinical isolates and are not induced during incubation with the inhibitorSemantic proximity Read ↗

Genotypic testing improves detection of antiviral resistance in human herpes simplex virus.Semantic proximity Read ↗

Genotypic characterization of herpes simplex virus DNA polymerase UL42 processivity factor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.